A review on Alzheimer's disease and its treatment

International Journal of Pharmaceutical Sciences

Volumn 2, Issue 3, 2010, Pages 701-707

  Anita, Kumari ^a   Kumar, Sharma Pramod ^a   Nitin, Sharma ^a   Kumar, Garg Vipin ^a   Zaihra, Anwer ^a  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid plaque; Dementia; Memory loss

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HUPERZINE A;

ALZHEIMER DISEASE; ARTICLE; BREATHING EXERCISE; CARBOHYDRATE DIET; CHOLINERGIC ACTIVITY; COMPUTER ASSISTED TOMOGRAPHY; DIETARY INTAKE; DISEASE CONTROL; ELECTROENCEPHALOGRAM; GINSENG; GUIDED IMAGERY; HEALTH EDUCATION; HUMAN; HYPNOSIS; LIFESTYLE MODIFICATION; MASSAGE; MEDITERRANEAN DIET; MINI MENTAL STATE EXAMINATION; MUSIC THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RELIGION; SALVIA OFFICINALIS; STRESS MANAGEMENT; UNSPECIFIED SIDE EFFECT;

EID: 79957707750     PISSN: None     EISSN: 09754725     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mori H. Molecular biology of Alzheimer's Disease and Animal Models. New York: Elsevier, 1998.
2. Frank and Gupta S. A review of antioxidants and Alzheimer's disease. Annals of Clinical Psychiatry. 2005; 17: 269-286.
3. Desai A.K. and Grossberg G. Diagnosis and treatment of Alzheimer's disease, Neurology. 2005; 64: 34-39.
4. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Reviews in Neuroscience. 2004; 5: 677-685.
5. Selkoe D.J. Defining molecular targets to prevent Alzheimer's disease. Archives of Neurology .2005; 62:192-195.
6. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatr. 1999; 6 (2): 137-47.
7. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991; 12 (10): 383-88.
8. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002; 25 (1): 22-26
9. Nistor M, Don M, Parekh M, et al. Alpha- and betasecretase activity as a function of age and betaamyloid in Down syndrome and normal brain. Neurobiol Aging. 007; 28 (10): 1493-1506.
10. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging. 2005; 26 (3): 383-389
11. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin Neurobiology of Aging. 2009. PMID: 19775776 [PubMed - as supplied by ublisher]
12. Bartzokis G, Lu PH, Mintz J. Quantifying age-related myelin breakdown with MRI: novel therapeutic breakdown. targets for preventing cognitive decline and Alzheimer's disease. Journal of Alzheimer's disease. 2004; 6:53-59.
13. Bartzokis G, Lu P, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimer's and Dementia. 2007; 3: 122.
14. Pratico D. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med; 2000:577-585.
15. "What is Alzheimer's disease?" Alzheimers.org.uk. August 2007.
16. http://www.alzheimers.org.uk/site/scripts/documents_i nfo.php?documentID=100.
17. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: FNS guideline. Eur J Neurol. 2007; 14(1):1-26.
18. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, Marder K, Albers MW, Stern Y, Devanand DP. A 10-item smell identification scale related to risk or Alzheimer's disease. Ann. Neurol. 2005; 58:155- 160.
19. Understanding stages and symptoms of Alzheimer's disease. National Institute on Aging.2007;10:26. http://www.nia.nih.gov/Alzheimers/Publications/stages.htm.
20. Andrew Gaeddert BA, AHG. The Herbal Approaches to Treating Memory Loss, Dementia, and Alzheimer's Disease. Acupuncture Today.2003; 4: 1-7.
21. Brice J. Volumetric MRI produces early warning on Alzheimer's disease. Diagnostic Imaging. 2009. http://www.diagnosticimaging.com/display/article/11319/1408373
22. Stahl SM. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action. J Clin Psychiatry. 2000; 61 (11): 813-814.
23. http://www.pspinformation.com/disease/alzheimers/alz heimers_risk.shtml
24. Caspar D et al. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett. 2000; 289: 210.
25. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 005; 2 (2): 131-6.
26. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009; 41 (1): 40- 59.
27. Dore S, Bastianetto S, Kar S, Quirion R. Protective and rescuing abilities of IGF-1 and some putative free radical scavengers against beta-amyloid-inducing oxicity in neurons. Ann NY Acad Sci. 1999; 890: 356-64.
28. Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. Faseb J. 2006; 20:1269-271.
29. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, et al. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients ith Alzheimer's disease. Eur J Neurol. 2008; 15:865- 8.
30. Panax Ginseng - Side Effects and Benefits.htm. The Herbal Resource http://www.herbal-supplementresource.com/
31. Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 2005;14:71-2.
32. Man SC, Durairajan SS, Kum WF, Lu JH, Huang JD, Cheng CF, et al. Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. J lzheimers Dis. 2008; 14:209-23.
33. Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals. 2005; 14:71-2.
34. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci. 2006; 27:619-25.
35. Wang, R. et al. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese folk medicine. Acta Pharmacol. Sin.2006; 27: 1-26.
36. Garden Sage (Salvia Officinalis) - Side Effects and Benefits.htm. The Herbal Resource. http://www.herbalsupplement-resource.com/
37. Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW. A randomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia.Gerontologist. 2001; 41: (1) 4-14.
38. Gitlin LN, Hauck WW, Dennis MP, Winter L. Maintenance of effects of the home environmental skillbuilding program for family caregivers and individuals with Alzheimer's disease and related disorders. J. Gerontol. A Biol. Sci. Med. Sci. 2005; 60 (3): 368-74.
39. Caspar D et al. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett. 2000; 289: 210-4.
40. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Disease and Associated Disorders. 2006; 20 (2): 112-117.